COVID-19: A Message from Our CEO
"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL LimitedRead Our Letter to Patients
CSL’s New Chief Scientific Officer
Dr. Andrew Nash has a lot on his plate, but he really wants to see your latest data.
Gratitude for Plasma Donors in Five Quotes
Last week, top U.S. officials, including Dr. Anthony Fauci, thanked those who donate plasma after recovering from COVID-19.
Convalescent Plasma and Hyperimmune Globulin
Find out 5 key differences between these two approaches to treating COVID-19.
Prepare, Perform, Prevail
Get 5 Lessons for navigating the rare disease Alpha 1 from a pioneering fighter pilot.
Disorder Channel Brings Rare Disease Stories to TV
Film festival founders create streaming channel for rare disease community.
Watch Online: CSL CEO at a White House Roundtable
Perreault made the case for a plasma-based hyperimmune to treat COVID-19.
Two-Minute Video: Rare Disease in Asia-Pacific
Get a quick introduction to The Economist Intelligence Unit survey about gaps in diagnosis and treatment.
CEO Paul Perreault at White House Roundtable
Perreault, representing the plasma industry, said an antibody treatment depends on additional donations from recovered patien…
Ironman Athlete Takes On Primary Immunodeficiency
The race has changed, but marathoner Stacy Ahearn is still pushing ahead following a rare disease diagnosis at age 40.